CD4 and total lymphocyte counts as predictors of HIV disease progression.
about
The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis.Prevalence of Anemia and Immunological Markers in HIV-Infected Patients on Highly Active Antiretroviral Therapy in Northeastern Nigeria.Early severe morbidity and resource utilization in South African adults on antiretroviral therapy.Total lymphocyte count is a good marker for HIV-related mortality and can be used as a tool for starting HIV treatment in a resource-limited setting.Technical performance evaluation of the MyT4 point of care technology for CD4+ T cell enumeration.Total lymphocyte count as a surrogate marker for CD4 count in resource-limited settings.High Rate of Non-detectable HIV-1 RNA Among Antiretroviral Drug Naive HIV Positive Individuals in NigeriaComparing absolute lymphocyte count to total lymphocyte count, as a CD4 T cell surrogate, to initiate antiretroviral therapy.Determining eligibility for antiretroviral therapy in resource-limited settings using total lymphocyte counts, hemoglobin and body mass index.Serum protein electrophoresis under effective control of HIV-1 disease progression.POC CD4 Testing Improves Linkage to HIV Care and Timeliness of ART Initiation in a Public Health Approach: A Systematic Review and Meta-Analysis.Performance Evaluation of the MyT4 Technology for Determining ART EligibilityTotal lymphocyte count of 1200 is not a sensitive predictor of CD4 lymphocyte count among patients with HIV disease in Kampala, UgandaSimple markers for the detection of severe immunosuppression in children with HIV infection in highly resource-scarce settings: experience from the Democratic Republic of Congo.HIV Drug-Resistant Patient Information Management, Analysis, and Interpretation.Clinical applications and availability of CD4+ T cell count testing in sub-Saharan Africa.Total lymphocyte count: not a surrogate marker for risk of death in HIV-infected Ugandan children.Absolute lymphocyte count as a predictor of Pneumocystis pneumonia in patients previously unknown to have HIVCurrent laboratory practices in flow cytometry for the enumeration of CD 4(+) T-lymphocyte subsets.Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD.Laboratory accuracy improvement in the uk neqas leucocyte immunophenotyping immune monitoring program: An eleven-year review via longitudinal mixed effects modeling.Correlation analysis on total lymphocyte count and CD4 count of HIV-infected patients.Plasma vitamin A and zinc levels in HIV-infected adults in Cape Town, South Africa.Equity and efficiency in HIV-treatment in South Africa: the contribution of mathematical programming to priority setting.HIV Treatment in Developing Countries.Immunological manifestations of HIV-infected children.Management of HIV and AIDS in the African context.Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY TrialResponse to the communication of M Hosp et al. on low-cost progression markers in HIV-1 seropositive Zambians
P2860
Q31082790-D5259EF0-BE1C-42FE-A6F5-5309E0415F26Q33415421-5FD1D1C0-2334-4087-8293-393617DA8B89Q33518021-1EDC351C-6403-428A-9643-ABF5C28D1085Q34007595-1B5147B6-2AC3-4117-A4D7-77FE3E4A9C31Q34206695-64D2A1D5-4F7A-421C-890B-9541109C0B59Q34296369-412B0C14-8531-45EA-80FB-A9BB3A7CB235Q34463096-766FC402-3D24-4C96-ACCD-AF85133CD4E8Q35183970-7E67DFAC-DFD8-4CF6-988E-AE13DA30911FQ35633250-D92D6CDD-041D-4D82-A097-B1BF29996801Q35728932-D37942D7-47A0-41BC-BD67-43CCE77689A1Q36016661-F2A6BE46-2A67-41F6-B8F6-3C85588C0940Q36174045-A0EE41E7-7678-4432-8A2A-1BCBFF3ECCC3Q36276325-3BC5EDFB-478C-4A51-921E-19ABC972D271Q36504397-A9E539BE-40A2-425F-B91E-6B68E495929EQ36765273-09983377-376D-4F6A-A3C4-C180FD908902Q37025655-6352126B-7614-4B80-A478-AD8EF2B65D10Q37290917-3BCD0DD2-301C-4183-9BF9-7133E8D5E38BQ38123819-5E54487E-A9B7-4317-A90D-F92819956357Q38398155-1EFB6DC7-D7AE-4A6E-A229-08ACAC5BB9DFQ38405625-D4975D07-7DD2-4DCE-BFD4-5B49E5AC2A94Q39290077-196BF3CC-BA97-4539-8931-591883016CEFQ43823698-E98D993E-38E8-45FB-AFB4-723C493F29C1Q44373890-687C6483-2764-4DC8-81F8-9E7BCA239948Q46318054-C133D665-3412-4F85-BBDB-A75CDD8CE9AFQ46472427-58E3BA19-6B99-4686-B109-D568BE752061Q46686239-1A19FF49-2806-4628-8F31-75040DD2F8A7Q47612384-3D9BAC38-AFAB-4BE5-8F4C-C59C8F1077D1Q56912555-82A179D2-4C5C-46E6-B781-18EDDDE44C49Q57235740-C61D244A-D336-4D25-A097-09F1A56D4D33
P2860
CD4 and total lymphocyte counts as predictors of HIV disease progression.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
CD4 and total lymphocyte counts as predictors of HIV disease progression.
@en
CD4 and total lymphocyte counts as predictors of HIV disease progression.
@nl
type
label
CD4 and total lymphocyte counts as predictors of HIV disease progression.
@en
CD4 and total lymphocyte counts as predictors of HIV disease progression.
@nl
prefLabel
CD4 and total lymphocyte counts as predictors of HIV disease progression.
@en
CD4 and total lymphocyte counts as predictors of HIV disease progression.
@nl
P2093
P356
P1476
CD4 and total lymphocyte counts as predictors of HIV disease progression.
@en
P2093
P304
P356
10.1093/QJMED/89.7.505
P407
P577
1996-07-01T00:00:00Z